Plain-language summary

This Phase 2 trial is testing Ruxolitinib, Positron emission tomography-computed tomography, and other medications for people whose adult T-cell leukemia/lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Ruxolitinib (DRUG): Administered orally twice daily | Positron emission tomography-computed tomography (PROCEDURE): Undergo PET-CT Scan | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow biopsy | Biopsy Procedure (PROCEDURE): Undergo tissue biopsy | Biospecimen Collection (PROCEDURE): Undergo blood sample collection

Drugs / treatments

Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy, Biopsy Procedure, Biospecimen Collection

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details